| Indicators | Browse All

IN8bio, Inc. (INAB)

Healthcare | Biotechnology | New York, United States | NasdaqCM
1.36 USD +0.01 (1.119%) ⇧ (July 14, 2026, 10:27 a.m. EDT)

Short-term:★★☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 4:23 a.m. EDT

The immediate outlook remains deeply bearish due to a catastrophic multi-year price collapse. Over the last three years, the stock has lost 96.54% of its value, with every single year showing negative returns. This relentless downward trajectory suggests the market has thoroughly priced out the business model, rendering any short-term technical bounce highly suspect. While recent news highlights a potential breakthrough in brain tumor therapy and analysts have set aggressive price targets, these are speculative hopes rather than realized fundamentals, especially given the company is burning significant cash with negative operating flows. For income investors, there is absolutely no yield to consider. The only conceivable case for a short-term trade is a contrarian bet on a sudden reversal based on the latest clinical data, but the structural damage to the share price makes this a high-risk scenario.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.065852
AutoARIMA0.065932
AutoETS0.066087
AutoTheta0.069205

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 39%
H-stat 3.50
Ljung-Box p 0.000
Jarque-Bera p 0.128
Excess Kurtosis -0.12
Attribute Value
Sector Healthcare
Debt to Equity Ratio 10.333
Market Cap 12,993,992
Forward P/E -1.28
Beta 0.22
Website https://in8bio.com

Info Dump

Attribute Value
52 Week Change -0.38106233
Address1 350 5th Avenue
Address2 Suite 5330
All Time High 309.57
All Time Low 1.17
Ask 1.76
Ask Size 2
Average Daily Volume10 Day 50,880
Average Daily Volume3 Month 59,190
Average Volume 59,190
Average Volume10Days 50,880
Beta 0.22
Bid 0.9648
Bid Size 2
Book Value 2.313
City New York
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 1.355
Current Ratio 10.501
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 1.37
Day Low 1.35
Debt To Equity 10.333
Display Name IN8bio
Earnings Timestamp End 1,754,596,800
Earnings Timestamp Start 1,754,596,800
Ebitda -17,839,000
Ebitda Margins 0.0
Enterprise To Ebitda 0.358
Enterprise Value -6,391,900
Eps Current Year -1.2425
Eps Forward -1.06
Eps Trailing Twelve Months -2.54
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 1.5107
Fifty Day Average Change -0.15569997
Fifty Day Average Change Percent -0.10306478
Fifty Two Week Change Percent -38.10623
Fifty Two Week High 2.73
Fifty Two Week High Change -1.375
Fifty Two Week High Change Percent -0.503663
Fifty Two Week Low 1.17
Fifty Two Week Low Change 0.18500006
Fifty Two Week Low Change Percent 0.15811972
Fifty Two Week Range 1.17 - 2.73
Financial Currency USD
First Trade Date Milliseconds 1,627,651,800,000
Float Shares 7,211,122
Forward Eps -1.06
Forward P E -1.278302
Free Cashflow -7,558,875
Full Exchange Name NasdaqCM
Full Time Employees 18
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.13395001
Held Percent Institutions 0.38112998
Implied Shares Outstanding 9,589,662
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-07-30
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,749,168,000
Last Split Factor 1:30
Long Business Summary IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Long Name IN8bio, Inc.
Market us_market
Market Cap 12,993,992
Market State REGULAR
Max Age 86,400
Message Board Id finmb_556676116
Most Recent Quarter 1,774,915,200
Net Income To Common -18,980,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 13,293,570
Number Of Analyst Opinions 4
Open 1.37
Operating Cashflow -14,537,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 646 600 6438
Previous Close 1.34
Price Eps Current Year -1.0905433
Price Hint 4
Price To Book 0.5858193
Profit Margins 0.0
Quick Ratio 10.167
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.014999986
Regular Market Change Percent 1.1194019
Regular Market Day High 1.37
Regular Market Day Low 1.35
Regular Market Day Range 1.35 - 1.37
Regular Market Open 1.37
Regular Market Previous Close 1.34
Regular Market Price 1.355
Regular Market Time 1,784,039,260
Regular Market Volume 2,221
Return On Assets -0.52746
Return On Equity -1.0355201
Sand P52 Week Change 0.20365608
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 9,589,662
Shares Percent Shares Out 0.0036000002
Shares Short 35,117
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 107,416
Short Name IN8bio, Inc.
Short Percent Of Float 0.004
Short Ratio 0.74
Source Interval 15
State NY
Symbol INAB
Target High Price 10.0
Target Low Price 4.0
Target Mean Price 6.25
Target Median Price 5.5
Total Cash 21,941,000
Total Cash Per Share 2.228
Total Debt 2,354,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.54
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 1.775275
Two Hundred Day Average Change -0.42027497
Two Hundred Day Average Change Percent -0.23673795
Type Disp Equity
Volume 2,221
Website https://in8bio.com
Zip 10,118